With growing interest by the Pharmaceutical industry to develop new healthcare solutions in the ophthalmic disease area, we have expanded the Ophthalmic and Retinal Disease Category of our Epiomic™ ...
Black Swan Analysis Blog
A look into...Uveitis
A look into...Migraine
Did you know that June, in terms of daylight hours, is the longest month of the year, despite being only 30 days long? Here’s something else you might not know about June, it’s Migraine Awareness...
A look into...Retinal Vein Occlusion
Retinal Vein Occlusion (RVO) is a disease in which type and location of occlusion, aetiology and visual complications are all linked to outcomes and treatment requirements. Therefore, knowing the...
Presenting at the forthcoming UK Pharma Forecasting Course
Black Swan Analysis will be running an Introduction to UK Pharma Forecasting on behalf of the BHBIA on June the 11th in London. This will be the 4th year in a row that Black Swan Analysis has run...
A look into...Testicular Cancer
April marks many things; Easter Sunday, the Thai New Year (this Sunday if you didn’t know) and Testicular Cancer Awareness Month.
A look into...Multiple Sclerosis
Multiple Sclerosis (MS) affects more than 2.3 million people worldwide; March is Multiple Sclerosis Education Awareness Month®, supported by the Multiple Sclerosis Foundation, with the theme, “MS...
Pharma Company and Agency Team Awards – Nominees 2014-15
Congrats to the Black Swan Analysis team for being nominated for this year’s BOBI award for the 'Agency I would most like to work with'. The competition for the top prize is looking tough this year,...
Now Available - USA and EU Hospital Procedure Data
Access to the Epiomic Hospital Procedure data for the USA and European Region is now available. As part of our core Epiomic database offering to healthcare clients, we have now made available on-line...
Now available, Atrial Fibrillation video demonstration of the Epiomic database
https://www.youtube.com/watch?v=tXrtIQ1SUVI
Can rare diseases be a viable option for the pharma industry?
In this article, Christopher Ehinger questions whether rare diseases are a viable option for the pharma industry. He looks at the total number of approvals and orphan drug designations in the US...